This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D).
The primary objective of this study was to evaluate participants' ability to use PaQ. A yes/no questionnaire was completed to evaluate each participant's ability to assemble, fill, prime, and apply PaQ, insert the cannula, administer bolus doses, and change the reservoir. In addition, understanding the signals emitted from PaQ and the action to be taken in response were also assessed.
Secondary objectives included:
c The transition from MDI to PaQ by the number of PaQ basal dose adjustments needed to maintain fasting glycemic control, total daily insulin dose (TDD), and number of meal boluses; (Dexcom Seven STS; Dexcom, San Diego, CA) was performed throughout the study.
Transition to PaQ
Participants received 1 h of training using the device and the PaQ Quick Start Guide as the primary teaching tool. Participants demonstrated their ability to assemble, apply, and safely use PaQ under supervision of the investigator. Participants were started on one of the five available preset PaQ basal doses using insulin aspart (Novo Nordisk A/S, Baegsvard, Denmark). The first selected basal dose was equal to or less than the basal dose used during baseline.
Investigators adjusted basal doses if 20-25% gains/reductions in fasting blood glucose were seen relative to baseline. There was no optimization of the insulin dose in order to achieve glycemic targets. Meal bolus doses were dependent on carbohydrate intake. The first 24 h on PaQ were spent at the clinical research unit under supervision of the investigators, and thereafter, participants were seen every 3 days. Seven-point glucose profiles were performed daily.
PaQ Treatment
Participants managed their blood glucose independently by using PaQ following the same regimen used during baseline and documenting their test results and therapy as described earlier.
Patient satisfaction and acceptance was assessed at the end of the study.
Data are presented as mean 6 SD if not otherwise specified. Paired t tests were used to determine statistical significance (P ,0.05). Categorical, qualitative variable summaries included the frequency and percentage of participants who were in the particular category. The denominator for the percentage calculation was based upon the total number of participants in the intent-to-treat population (i.e., all participants who received PaQ at least once).
RESULTS

Twenty individuals with T2D (5 females)
were enrolled in the study. Transition was successful in 14 of 19 participants using the first basal dose, and 5 required another dose change. TDD at baseline (60.4 6 19.1 U) was similar to PaQ treatment (57.1 6 14.6 U). A total of 50% of participants reduced their TDD by 26% (8-23 U) at study end. TDD for five patients remained unchanged (TDD within 10% of baseline dose), whereas TDD for four patients increased by $10% during PaQ treatment. The average number of daily bolus doses showed a slight increase during PaQ treatment (3.7 vs. 4.2; P = 0.095).
Changes in SMBG during PaQ treatment showed a trend toward improved glycemic control (pre-and postbreakfast and bedtime, all not significant) (Fig.  1C) . CGM data revealed a reduction in average 24-h glucose exposure of 2190.3 mg/dL (P = 0.18) compared with baseline. The reduction overnight was 2101.7 mg/dL (P = 0.06). Time within target (70-140 mg/dL) increased from 30.7 to 35.6% (P = 0.26). The percentage of time that glucose values were ,50 and ,70 mg/dL showed a slight, but nonsignificant, increase during PaQ treatment.
Patient-reported data from the deviceuse questionnaire revealed a high level of PaQ satisfaction and acceptance. All but one scored .4.00, indicating high and very high device satisfaction, and the mean "acceptance" score ranked between high and very high.
No serious adverse events occurred during the study. Fourteen of 19 participants (73.7%) experienced hypoglycemic episodes, but none of these were associated with PaQ malfunction. The number of participants who experienced hypoglycemia was lower during PaQ treatment compared with baseline (Fig.  1D) . A total of six device-associated hyperglycemic episodes (nonfunctional bolus button [n = 1], cannula dislodgment from skin [n = 2], device falling-off body [n = 1]) were experienced by 4 of 19 participants (21%). For two episodes in one participant, the causes remain unclear.
CONCLUSIONS
Data from this feasibility study suggest that PaQ is an easy-to-use, safe, and highly accepted continuous subcutaneous insulin infusion device. These findings are important because ease of use and improved patient satisfaction may result in better adherence and improved clinical outcomes (10) . While the study is limited due to its size and lack of control group, the data suggest that PaQ may achieve glycemic control comparable to MDI. Additional studies are needed to elucidate the benefits of PaQ treatment in diverse diabetes populations.
